Konstantinos Sfaelos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Konstantinos Sfaelos has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Eleftheria Tampouratzi
Department of Dermatology and Venereology, “Tzaneio” General Hospital of Pireus, 18536 Pireus, Greece
6 shared publications Sophia Georgiou
Department of Dermatology, Medical School, General University Hospital University of Patras Patras Greece
5 shared publications- Elizabeth Lazaridou
Second Dermatology Department, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
4 shared publications John Katsantonis
Dermatological Department Tzaneio General Hospital Piraeus Greece
4 shared publicationsMarkos Papakonstantis
Clinic of Dermatology 401 General Military Hospital of Athens Athens Greece
4 shared publicationsPantelis Panagakis
Department of Dermatology and Venereology NHS Andreas Syggros Hospital Athens Greece
4 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by MDPI AG in Therapeutics
- Vol. 2 (4) , 19
Using Conjoint Analysis to Elicit Benefit–Risk Preferences for Different Treatment Options Among Psoriasis Patients Receiving Systemic Therapy
Background: Psoriasis has a huge impact on a patient’s life. Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. The modern strategy for psoriasis should be focused on human-centric treatment that recognizes the needs and preferences of patients with a goal for safe, effective, quality and acceptable health services for a lifetime. The aim of this analysis was to capture patients’ preferences with moderate-to-severe psoriasis regarding various treatment attributes. Methods: A specialized questionnaire containing four attributes with three levels, each, was used, followed by an orthogonal plan based on conjoint analysis. Nine combinations of therapeutic scenarios were produced as a result, to investigate participants’ preferences. Respondents were asked to rank alternatives from best to worst. Results: The risk of developing pneumonia or other serious infections within a decade seems to be higher in patients with an implied assigned value of 37. The second attribute was the type and frequency of the administration with a value of 27, followed by the treatment effectiveness with great improvement of body surface with a value of 25. The lowest utility (11) was the sustainability of early remission of psoriasis. Conclusions: Psoriasis patients want safe, effective and easy to administer treatments.
- 31 October 2025
- Published by MDPI AG in Therapeutics
- Vol. 2 (4) , 19
Open AccessUsing Conjoint Analysis to Elicit Benefit–Risk Preferences for Different Treatment Options Among Psoriasis Patients Receiving Systemic Therapy
Background: Psoriasis has a huge impact on a patient’s life. Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. The modern strategy for psoriasis should be focused on human-centric treatment that recognizes the needs and preferences of patients with a goal for safe, effective, quality and acceptable health services for a lifetime. The aim of this analysis was to capture patients’ preferences with moderate-to-severe psoriasis regarding various treatment attributes. Methods: A specialized questionnaire containing four attributes with three levels, each, was used, followed by an orthogonal plan based on conjoint analysis. Nine combinations of therapeutic scenarios were produced as a result, to investigate participants’ preferences. Respondents were asked to rank alternatives from best to worst. Results: The risk of developing pneumonia or other serious infections within a decade seems to be higher in patients with an implied assigned value of 37. The second attribute was the type and frequency of the administration with a value of 27, followed by the treatment effectiveness with great improvement of body surface with a value of 25. The lowest utility (11) was the sustainability of early remission of psoriasis. Conclusions: Psoriasis patients want safe, effective and easy to administer treatments.
- Open Access
- 10 July 2025
- Published by MDPI AG in Preprints.org
Using Conjoint Analysis to Elicit Benefit-Risk Preferences for Different Treatment Options Among Psoriasis Patients Receiving Systemic Treatment
Background: Psoriasis has a huge impact on patient’s life. Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discord-ance between individual preferences and recommended treatments. The modern strategy for psoriasis should be focused on human centric treatment that recognizes the needs and preferences of patients with a goal for safe, effective, quality, and ac-ceptable health services for a lifetime. The aim of this analysis was to capture patients’ preferences with moderate-to-severe psoriasis regarding various treatment attributes. Methods: Development of a specialized questionnaire containing four attributes with three levels each was used, followed by an orthogonal plan based on conjoint analysis. Nine combinations of therapeutic scenarios were produced as a result, to investigate participants’ preferences. Respondents were asked to rank alternatives from best to worst. Results: The risk of developing pneumonia or other serious infection within a decade, seems to affect more the overall preference of patients with an implied assigned value of 37. The second attribute was the type and frequency of the administration with a value of 27 followed by the treatment effectiveness with great improvement of body surface with a value of 25. The lowest utility (11) was sustainability of long-term re-mission of psoriasis. Conclusions: Psoriasis patients want safe, effective, and easy to administer treatments.
- 10 July 2025
- Published by MDPI AG in Preprints.org
Open AccessUsing Conjoint Analysis to Elicit Benefit-Risk Preferences for Different Treatment Options Among Psoriasis Patients Receiving Systemic Treatment
Background: Psoriasis has a huge impact on patient’s life. Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discord-ance between individual preferences and recommended treatments. The modern strategy for psoriasis should be focused on human centric treatment that recognizes the needs and preferences of patients with a goal for safe, effective, quality, and ac-ceptable health services for a lifetime. The aim of this analysis was to capture patients’ preferences with moderate-to-severe psoriasis regarding various treatment attributes. Methods: Development of a specialized questionnaire containing four attributes with three levels each was used, followed by an orthogonal plan based on conjoint analysis. Nine combinations of therapeutic scenarios were produced as a result, to investigate participants’ preferences. Respondents were asked to rank alternatives from best to worst. Results: The risk of developing pneumonia or other serious infection within a decade, seems to affect more the overall preference of patients with an implied assigned value of 37. The second attribute was the type and frequency of the administration with a value of 27 followed by the treatment effectiveness with great improvement of body surface with a value of 25. The lowest utility (11) was sustainability of long-term re-mission of psoriasis. Conclusions: Psoriasis patients want safe, effective, and easy to administer treatments.
- Open Access
- 15 May 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (3) , 55
The Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker of Fournier’s Gangrene Severity: A Meta-Analysis
Background/Objectives: Fournier’s Gangrene (FG) is a severe and potentially fatal necrotizing infection of the perianal and genital regions, which necessitates prompt therapeutic interventions to prevent disease progression. Accruing evidence from recent research indicates that the neutrophil‒to-lymphocyte ratio (NLR) can predict clinical severity and mortality risk in patients with critical illnesses across various etiologies. This meta-analysis aimed to assess the efficacy of NLR as a prognostic indicator for mortality in patients with FG. Methods: An electronic literature search was conducted across several databases from their inception to 31 May 2024, following a predetermined protocol. Study quality was evaluated using the Cochrane risk of bias tool. A random-effect model was utilized to synthesize the available data. Results: Twelve studies reporting on 767 patients were included in the meta-analysis. Higher NLR levels at presentation were recorded in non-survivors than in survivors (MD = 4.49 [95% CI: 0.67–8.32]; p = 0.02). A 76% increased mortality risk was detected for patients with an NLR ≥ 8 (1.76 RR [1.35–2.3], p = 0.0001), and the mortality risk was more than twofold greater for patients with an NLR ≥ 10 compared to the remaining patients (RR = 2.31 [1.27–4.21], p = 0.006). All included studies exhibited a moderate to serious risk of bias. Conclusions: This meta-analysis reveals that the NLR represents a promising biomarker that can serve as a prognostic indicator in patients with FG. Future studies should address the establishment of proper disease-specific cutoff values to aid in clinical decision-making.
- 15 May 2025
- Published by MDPI AG in Infectious Disease Reports
- Vol. 17 (3) , 55
Open AccessThe Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker of Fournier’s Gangrene Severity: A Meta-Analysis
Background/Objectives: Fournier’s Gangrene (FG) is a severe and potentially fatal necrotizing infection of the perianal and genital regions, which necessitates prompt therapeutic interventions to prevent disease progression. Accruing evidence from recent research indicates that the neutrophil‒to-lymphocyte ratio (NLR) can predict clinical severity and mortality risk in patients with critical illnesses across various etiologies. This meta-analysis aimed to assess the efficacy of NLR as a prognostic indicator for mortality in patients with FG. Methods: An electronic literature search was conducted across several databases from their inception to 31 May 2024, following a predetermined protocol. Study quality was evaluated using the Cochrane risk of bias tool. A random-effect model was utilized to synthesize the available data. Results: Twelve studies reporting on 767 patients were included in the meta-analysis. Higher NLR levels at presentation were recorded in non-survivors than in survivors (MD = 4.49 [95% CI: 0.67–8.32]; p = 0.02). A 76% increased mortality risk was detected for patients with an NLR ≥ 8 (1.76 RR [1.35–2.3], p = 0.0001), and the mortality risk was more than twofold greater for patients with an NLR ≥ 10 compared to the remaining patients (RR = 2.31 [1.27–4.21], p = 0.006). All included studies exhibited a moderate to serious risk of bias. Conclusions: This meta-analysis reveals that the NLR represents a promising biomarker that can serve as a prognostic indicator in patients with FG. Future studies should address the establishment of proper disease-specific cutoff values to aid in clinical decision-making.
- Open Access
The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma
With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders.
Open AccessThe Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma
With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders.
- 3 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (6) , 1121-1130
Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
Background: Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real‐life data remain scarce. BrIDGE was an observational, prospective, single‐cohort, multicentre study that recruited patients with moderate‐to severe plaque psoriasis in Greece.Objectives: The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short‐term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12–16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.Methods: Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, ‘worst case’ and ‘best case’ scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables.Results: Based on the ‘as observed data’, 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12–16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12–16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%.Conclusions: Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate‐to‐severe psoriasis patients.
- 3 February 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (6) , 1121-1130
Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
Background: Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real‐life data remain scarce. BrIDGE was an observational, prospective, single‐cohort, multicentre study that recruited patients with moderate‐to severe plaque psoriasis in Greece.Objectives: The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short‐term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12–16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.Methods: Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, ‘worst case’ and ‘best case’ scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables.Results: Based on the ‘as observed data’, 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12–16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12–16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%.Conclusions: Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate‐to‐severe psoriasis patients.
- Open Access
- 11 October 2023
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 16 (2) , 9689
Translation and validation of patient-oriented eczema measure in the Greek language
Translating and validating the Greek version of the Patient Oriented Eczema Measure (POEM) was our goal. A parallel backtranslation process was used to translate POEM. A total of fiftynine adult atopic dermatitis patients were enlisted to assess validity and reliability. Through patient interviews with physicians, a questionnaire comprising demographics, POEM, and the dermatology life quality index (DLQI) was filled out. 3-7 days after the first visit, a second POEM completion was conducted. The POEM items conducted with study participants demonstrated a good level of internal consistency (Cronbach’s alpha = 0.88), and no overall floor and ceiling effects were found. There was a significant correlation between the DLQI and POEM scores (Spearman rho =0.71; p<0.001). The POEM score between interviews showed an average intraclass correlation coefficient (95% confidence interval) of 0.89 (0.80, 0.94), indicating good to excellent test-retest reliability. Patient-reported outcome measures are becoming more and more common in Greece, so it’s critical to have access to Greek translations of validated instruments that are frequently used in literature.
- 11 October 2023
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 16 (2) , 9689
Open AccessTranslation and validation of patient-oriented eczema measure in the Greek language
Translating and validating the Greek version of the Patient Oriented Eczema Measure (POEM) was our goal. A parallel backtranslation process was used to translate POEM. A total of fiftynine adult atopic dermatitis patients were enlisted to assess validity and reliability. Through patient interviews with physicians, a questionnaire comprising demographics, POEM, and the dermatology life quality index (DLQI) was filled out. 3-7 days after the first visit, a second POEM completion was conducted. The POEM items conducted with study participants demonstrated a good level of internal consistency (Cronbach’s alpha = 0.88), and no overall floor and ceiling effects were found. There was a significant correlation between the DLQI and POEM scores (Spearman rho =0.71; p<0.001). The POEM score between interviews showed an average intraclass correlation coefficient (95% confidence interval) of 0.89 (0.80, 0.94), indicating good to excellent test-retest reliability. Patient-reported outcome measures are becoming more and more common in Greece, so it’s critical to have access to Greek translations of validated instruments that are frequently used in literature.
- Open Access
- 19 April 2023
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 6 (1) , e39451
Patient Engagement With the Myderma Platform for Psoriasis During the COVID-19 Pandemic
- 19 April 2023
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 6 (1) , e39451
Open AccessPatient Engagement With the Myderma Platform for Psoriasis During the COVID-19 Pandemic
- Open Access
- 19 January 2023
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 34 (1) , 2147390
Preoperative and postoperative evaluation of survivin in peripheral blood of patients with non-melanoma skin cancers. A pilot study
To evaluate the preoperative and postoperative survivin [an apoptosis inhibitor (IAP) protein] peripheral blood levels and C-Reactive Protein (CRP), in patients with basal cell carcinoma (BCC) and ...
- 19 January 2023
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 34 (1) , 2147390
Open AccessPreoperative and postoperative evaluation of survivin in peripheral blood of patients with non-melanoma skin cancers. A pilot study
To evaluate the preoperative and postoperative survivin [an apoptosis inhibitor (IAP) protein] peripheral blood levels and C-Reactive Protein (CRP), in patients with basal cell carcinoma (BCC) and ...